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Table 1. Effect of PRRSV-RS vaccine on growth performance of finisher pigs1
Treatment2
Item Control Vaccinated Probability, P <
Initial	wt,	lb 58.4	±	1.7 58.7	±	1.7 0.90
d	0	to	112
					ADG,	lb 1.96	±	0.03 1.93	±	0.03 0.45
					ADFI,	lb 5.35	±	0.08 5.36	±	0.08 0.94
					F/G 2.74	±	0.02 2.78	±	0.02 0.15












Table 2. Effect of PRRSV-RS vaccine on within-period and cumulative mortality1
Treatment2
Probability,	P <Item Control Vaccinate
Inventory
					Processing3 781 780 ---
					Weaning4 707 725 ---
					Entry	to	finisher5 641 658 ---
					Off	test6,7 529 535 ---
Within-period	mortality
					Processing	to	weaning,	% 9.5 7.1 0.08
					Nursery,	% 9.3 9.2 0.95
					Finisher,	% 4.4 5.9 0.20
Cumulative	mortality
					Processing	to	weaning,	% 9.5 7.1 0.08
					Processing	to	end	of	nursery,	% 17.9 15.6 0.23
					Processing	to	off	test,	%6 21.5 20.6 0.67
1	A	total	of	1,561	pigs	(barrows	or	gilts)	from	140	litters	across	5	sow	farms	were	assigned	to	1	of	2	treatments	
at	processing	(4	d	of	age)	by	randomly	assigning	entire	litters	to	either	the	vaccinated	or	non-vaccinated	control	
groups.	Control	and	vaccinated	pigs	were	comingled	in	the	nursery	and	then	separated	by	vaccine	treatment	and	
gender	in	the	finisher	barn.	Mortality	was	tracked	for	controls	and	vaccinates	from	processing	to	the	end	of	the	
finishing	portion	of	the	trial.
2	Treatments	were:	Control	=	no	vaccine	administered	and	Vaccinated	=	1	mL	PRRSV-RS	administered	intra-
muscularly	at	processing	and	weaning.	
3	4	d	of	age.	
4	Weaning	age	range	was	20	to	26	d	of	age.
5	Entry-to-finisher	age	range	was	60	to	66	d	of	age.
6	Off-test	age	range	was	187	to	193	d	of	age.
7	Inventory	at	off	test	(d	112)	excludes	pigs	marketed	(84	controls	and	84	vaccinates)	on	d	90	of	the	trial.
